ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TNXP vs GNLX // NET PROFIT MARGIN

Tonix Pharmaceuticals Holding Corp. (NASDAQ) VS. Genelux Corporation (NASDAQ) • 15-METRIC TALLY: TNXP 2 — GNLX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TNXP VS. GNLX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TNXP GNLX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 49.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin ACTIVE -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 29.80% 0.00% +29.80 TNXP /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 2/9 +3.00 TNXP /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 19.1 37.3 -18.20 GNLX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $88.3M $90.5M -$2.2M GNLX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TNXP REV GNLX REV TNXP GROSS % GNLX GROSS % TNXP FCF GNLX FCF
FY 2025 $13.1M $8.0K 49.3% — -$103.2M -$26.4M
FY 2024 $10.1M $8.0K 23.1% — -$61.0M -$21.6M
FY 2023 $7.8M $170.0K — — -$102.0M -$20.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TNXP // BETA —
GNLX // BETA —